FIRST-IN-HUMAN STUDY OF MLS-101, A POTENT AND HIGHLY …
WEBMar 5, 2023 · MLS-101 is a well-tolerated and highly selective aldosterone synthesis inhibitor. In contrast with aldosterone receptor blockers, which increase aldosterone production, MLS-101 produced comparable renal effects while substantially reducing circulating aldosterone.
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS …
WEBNov 16, 2022 · MLS-101, a highly selective investigational aldosterone synthase inhibitor, at doses of 50 mg and 100 mg once daily (QD), met its primary endpoint with statistically significant and clinically...
HIGHLY EFFECTIVE BLOOD PRESSURE LOWERING WITH MLS-101, …
WEBMar 4, 2023 · MLS-101 demonstrated robust BP reduction during wakefulness and sleep. This is the first antihypertensive in a randomized, placebo-controlled trial demonstrated to be uniquely effective in an obese hypertensive population.
Mineralys Therapeutics Closes $118 Million Oversubscribed Series …
WEBJun 8, 2022 · MLS-101 is a highly selective and potent aldosterone synthase inhibitor, licensed from Mitsubishi Tanabe Pharma Corporation, that is being investigated for the treatment of hypertension.
Lorundrostat - Wikipedia
WEBLorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure.
Lorundrostat Safely Lowers Blood Pressure in Uncontrolled …
WEBSep 11, 2023 · Lorundrostat (MLS-101) ― an investigational medication that works by lowering aldosterone production ― safely and effectively lowered blood pressure (BP) in patients with hypertension refractory to standard medical treatment.
WEBSafety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension Sponsor: Mineralys Therapeutics, Inc. 150 N. Radnor Chester Rd. –
WEBMLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
Study To Evaluate The Efficacy And Safety Of Mls-101 In Subjects …
WEBThis study is a Phase 2 trial to evaluate the blood pressure-lowering effects of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a standardized anti-hypertensive (AHT) medication regimen, in subjects with uncontrolled and/or treatment-resistant hypertension.
Lorundrostat in Uncontrolled Hypertension
WEBThe purpose of this study is to assess the blood pressure lowering effect of an experimental drug called lorundrostat (MLS 101) in combination with medications (that are approved by the U.S. Food and Drug Administration-FDA) used for treating high blood pressure in people with uncontrolled hypertension. Uncontrolled hypertension is a condition ...